BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 23517534)

  • 1. A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
    Lv C; Ma Y; Wu N; Yan S; Zheng Q; Sun Y; Li S; Fang J; Yang Y
    World J Surg Oncol; 2013 Mar; 11():76. PubMed ID: 23517534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
    Natukula K; Jamil K; Pingali UR; Suresh Attili VS; Naidu Madireddy UR
    Asian Pac J Cancer Prev; 2013; 14(8):4661-6. PubMed ID: 24083721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
    Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
    Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
    Hirsh V; Soulieres D; Duclos M; Faria S; Del Vecchio P; Ofiara L; Ayoub JP; Charpentier D; Gruber J; Portelance L; Souhami L
    J Thorac Oncol; 2007 Oct; 2(10):927-32. PubMed ID: 17909355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
    Paramanathan A; Solomon B; Collins M; Franco M; Kofoed S; Francis H; Ball D; Mileshkin L
    Clin Lung Cancer; 2013 Sep; 14(5):508-12. PubMed ID: 23792009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.
    Laskin JJ; Nicholas G; Lee C; Gitlitz B; Vincent M; Cormier Y; Stephenson J; Ung Y; Sanborn R; Pressnail B; Nugent F; Nemunaitis J; Gleave ME; Murray N; Hao D
    J Thorac Oncol; 2012 Mar; 7(3):579-86. PubMed ID: 22198426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
    Fang H; Lin RY; Sun MX; Wang Q; Zhao YL; Yu JL; Tian Y; Wang XY
    Asian Pac J Cancer Prev; 2014; 15(24):10967-70. PubMed ID: 25605210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
    Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
    Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
    Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M
    J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
    Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
    Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
    Li CH; Liu MY; Liu W; Li DD; Cai L
    Asian Pac J Cancer Prev; 2014; 15(2):731-6. PubMed ID: 24568487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
    Wang J; Wu N; Lv C; Yan S; Yang Y
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):463-469. PubMed ID: 30474757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
    Detterbeck FC; Socinski MA; Gralla RJ; Edelman MJ; Jahan TM; Loesch DM; Limentani SA; Govindan R; Zaman MB; Ye Z; Monberg MJ; Obasaju CK
    J Thorac Oncol; 2008 Jan; 3(1):37-45. PubMed ID: 18166839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
    Edelman MJ; Belani CP; Socinski MA; Ansari RH; Obasaju CK; Chen R; Monberg MJ; Treat J;
    J Thorac Oncol; 2010 Jan; 5(1):110-6. PubMed ID: 20035187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution.
    Inal A; Kaplan MA; Kucukoner M; Urakci Z; Karakus A; Isikdogan A
    Asian Pac J Cancer Prev; 2012; 13(5):1837-40. PubMed ID: 22901132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
    Chen LK; Liang Y; Yang QY; Xu F; Zhou NN; Xu GC; Liu GZ; Wei WD
    Asian Pac J Cancer Prev; 2012; 13(5):1863-7. PubMed ID: 22901137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
    Weissman CH; Reynolds CH; Neubauer MA; Pritchard S; Kobina S; Asmar L
    J Thorac Oncol; 2011 Feb; 6(2):358-64. PubMed ID: 21206386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Banna GL; Lipari H; Nicolosi M; Basile A; Fraggetta F; Vaglica M; Marletta F; Urso OE; Ippolito M; Terminella A; Saita S
    Med Oncol; 2013 Jun; 30(2):533. PubMed ID: 23512427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC).
    Schallier D; Bral S; Ilsen B; Neyns B; Fontaine C; Decoster L; De Mey J; Meysman M; De Grève J
    J Thorac Oncol; 2009 Jun; 4(6):728-35. PubMed ID: 19404217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.